Pays: Canada
Langue: anglais
Source: Health Canada
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)
PRO DOC LIMITEE
J01FA10
AZITHROMYCIN
250MG
TABLET
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250MG
ORAL
30/100
Prescription
OTHER MACROLIDES
Active ingredient group (AIG) number: 0126072001; AHFS:
APPROVED
2008-09-25
PRODUCT MONOGRAPH PR PRO-AZITHROMYCINE Azithromycin Tablets 250 mg USP ANTIBACTERIAL AGENT PRO DOC LTÉE 2925, boul. Industriel Laval, Québec H7L 3W9 DATE OF REVISION: May 28, 2019 Control number: 227600 _PRO-AZITHROMYCINE Product Monograph _ _Page 2 of 71_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................6 WARNINGS AND PRECAUTIONS ....................................................................................6 ADVERSE REACTIONS ....................................................................................................11 DRUG INTERACTIONS .....................................................................................................18 DOSAGE AND ADMINISTRATION.................................................................................23 OVERDOSAGE ...................................................................................................................24 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................29 PART II: SCIENTIFIC INFORMATION ................................................................................30 PHARMACEUTICAL INFORMATION ............................................................................30 CLINICAL TRIALS ............................................................................................................31 DETAILED PHARMACOLOGY................................................................. Lire le document complet